Meeting
2018 Gastrointestinal Cancers Symposium
Discovery and validation of a quantitative, stromal-associated imaging biomarker of pancreatic ductal adenocarcinoma (PDAC).
Authors
Mohamed Zaid
University of Texas MD Anderson Cancer Center, Houston, TX
Mohamed Zaid , Baishali Chaudhury , Gauri R. Varadhachary , Matthew H. G. Katz , Joseph M. Herman , Eric P. Tamm , Eugene Jon Koay
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 228)
DOI
10.1200/JCO.2018.36.4_suppl.228
Abstract #
228
Poster Bd #
B3
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Single-cell immune mapping of adenoid cystic carcinoma (ACC) reveals potential therapeutic targets for the aggressive solid subtype.
First Author: Luana Guimaraes de Sousa
Poster
2018 Gastrointestinal Cancers Symposium
Quantitative PET-MRI for early treatment response assessment in pancreatic ductal adenocarcinoma.
First Author: Martin Valera Consunji
Poster
2017 Gastrointestinal Cancers Symposium
Tumor interface stability on CT imaging is an early marker of response to cytotoxic therapy in pancreatic ductal adenocarcinoma.
First Author: Christopher Wilke
Poster
2024 ASCO Annual Meeting
Cost-effectiveness of a circulating tumor fraction molecular biomarker for treatment response monitoring.
First Author: Zachary Rivers